Do you need a break when switching between Wegovy and Mounjaro?

You're already on Wegovy and wondering whether Mounjaro needs a gap first

Picture this: you have been on Wegovy for several months, you've heard that tirzepatide produced greater average weight loss than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, and you want to explore the switch. The obvious question is whether you need to let semaglutide clear your system before the first Mounjaro pen.

The short answer is no, not in the way you might expect. There is no mandated washout window between the two medicines in UK clinical practice. Because both reduce appetite through gut-hormone pathways and slow gastric emptying, running them together would be inappropriate, but stopping one and starting the other on your next scheduled injection day is the approach most prescribers follow. The transition is typically timed dose-to-dose so there is no meaningful overlap and no unnecessary gap that would let your progress reverse sharply.

That said, the dose you are currently on matters. If you are mid-titration on Wegovy rather than at a maintenance dose, your prescriber will think carefully about where Mounjaro's schedule should begin. Starting tirzepatide at 2.5mg is the standard approach regardless of what you were on before, because the first pen exists to let your body adjust to the new medicine, not to carry over your previous therapeutic level. More on what the washout question means in practice is covered in our dedicated page on the topic.

The same question in reverse: switching from Mounjaro to Wegovy

The direction of travel changes the practical picture slightly. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide acts on the GLP-1 pathway only, so you are moving from a broader mechanism to a narrower one. There is no pharmacological reason this requires a rest period, but a prescriber will want to understand why the switch is happening before issuing anything.

Reasons people move from Mounjaro to Wegovy include tolerability at higher doses, supply considerations, or a clinical decision to try the 7.2mg semaglutide option following its MHRA approval in January 2026. Whatever the reason, the same principle applies: the switch is usually timed to the next scheduled injection, and Wegovy's own titration schedule starts from scratch. Carrying over a high Mounjaro dose and expecting Wegovy to pick up at an equivalent level is not how it works, and a prescriber familiar with both medicines will set that expectation clearly from the start.

If you are currently on Mounjaro through another provider and want to continue treatment with us, our page on moving from Mounjaro to Wegovy walks through how that process works, including what evidence transfer patients are asked to provide.

A quick comparison of the two medicines side by side

Before exploring whether a break is needed, it helps to see the two medicines clearly, and our full Wegovy v Mounjaro comparison goes into much greater detail if you want to dig into the differences beyond the summary below. The table draws on NHS medicines guidance and the published trial data.

Both are prescription-only medicines requiring clinical assessment before any prescription is issued. The NHS tirzepatide page and the NHS semaglutide page carry patient-level information on both, including side-effect profiles and storage instructions.

What your prescriber actually weighs up before approving the switch

A one-minute check worth doing before any consultation: pull up your current pen and note the exact dose and the date of your last injection. That information takes the prescriber from a five-minute conversation to a two-minute one, because the main variables they need are dose, duration, reason for switching, and any side effects you experienced. Having it ready is the difference between a same-day approval and a follow-up question.

Beyond the logistics, the prescriber is thinking about a few things. How well did you tolerate the previous medicine? Did gastrointestinal side effects settle, or are they still a factor? Is the switch being driven by plateauing results, supply, or clinical recommendation? And crucially, are there any new health changes since your original assessment that affect which medicine is appropriate now? If you are also wondering whether you can swap between Wegovy and Mounjaro more than once, that page covers the considerations your prescriber will work through with you.

None of this is bureaucratic. It reflects the fact that these medicines work on appetite, digestion and blood sugar in ways that interact with other conditions and medicines you might be taking. The guidance on choosing between the two covers those factors in more depth, and our clinical team reviews every switch request individually. There is no algorithm making that call.

Which medicine suits you after a previous course of the other is a clinical decision our prescribers make with you, and if you have questions about whether it is ever appropriate to mix Mounjaro and Wegovy in any way, that page explains the clinical position clearly. Speak to our prescribers and start your free consultation today.